Study types
- article 7
- erratum 1
- other 1
Condition tags
- endometriosis 6
- dysmenorrhea 4
- chronic_pelvic_pain 1
- adenomyosis 1
- dyspareunia 1
Top journals
Frequent coauthors
- Böttcher B 5
- L. Wildt 5
- Bettina Toth 4
- Strowitzki T 3
- Wildt L 3
- Ariane Germeyer 2
- Beate Ditzen 2
- Geiser M 2
- Beata Seeber 2
- Eckstein M 2
BACKGROUND: Endometriosis is often associated with severe dysmenorrhea, pelvic pain and dyspareunia and has a high impact on daily life as well as sexuality. Quality of partnership positively influences the course of various diseases and ab…
Summary Fertility preservation in women has become well established over the last two decades. Nevertheless, options for cancer survivors need to be improved to regain ovarian functioning, ideally leading to pregnancy and live birth. Techni…
BackgroundChronic pelvic pain, in particular dysmenorrhoea, is a significant yet unresolved healthcare problem in gynaecology. As interoceptive sensitivity and underlying neural mechanisms remain incompletely understood, this functional mag…
STUDY OBJECTIVE: To study the safety and efficacy of dienogest 2 mg in adolescents with suspected endometriosis. DESIGN: A 52-week, open-label, single-arm study. SETTING: In 21 study centers, in 6 European countries. PARTICIPANTS: Adoles…
PurposeSeveral studies on the quality of life in patients with endometriosis have been performed with conflicting results. This cross-section survey examines the influence of endometriosis on the psychological well-being and the quality of …
PURPOSE: In a series of publications, we had developed the concept that uterine adenomyosis and pelvic endometriosis as well as endometriotic lesions at distant sites of the body share a common pathophysiology with endometriosis constitutin…
STUDY QUESTION: What is the safe and pharmacodynamically active dose range for PDC31 (prostaglandin F2α receptor inhibitor) in patients with primary dysmenorrhea (PD)? SUMMARY ANSWER: The 1 mg/kg/h dose of PDC31 appears to be safe and poten…